Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of MK-5172 + MK-3682 + (MK-8742 or MK-8408) in HCV GT3-6
NCT02332720Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of uprifosbuvir, ruzasvir and grazoprevir in hepatitis C (HCV) (22 arms), sponsored by Merck & Co. Primary endpoints: Sustained Virologic Response at Follow-up Week 12, Number of Participants Experiencing an Adverse Event up to 40 weeks and 1 more. Started Jan 2015; status: completed.
02
Drugs
uprifosbuvirruzasvirgrazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02332720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332720.